Hickling J - Search Results

1

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H. Kaufmann AM, et al. Among authors: hickling j. Clin Cancer Res. 2002 Dec;8(12):3676-85. Clin Cancer Res. 2002. PMID: 12473576

2

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.

Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL. Davidson EJ, et al. Among authors: hickling j. Cancer Res. 2003 Sep 15;63(18):6032-41. Cancer Res. 2003. PMID: 14522932

3

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.

Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC. Baldwin PJ, et al. Among authors: hickling jk. Clin Cancer Res. 2003 Nov 1;9(14):5205-13. Clin Cancer Res. 2003. PMID: 14614000 Clinical Trial.

4

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.

Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH. Smyth LJ, et al. Among authors: hickling jk. Clin Cancer Res. 2004 May 1;10(9):2954-61. doi: 10.1158/1078-0432.ccr-03-0703. Clin Cancer Res. 2004. PMID: 15131030 Clinical Trial.

5

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. Borysiewicz LK, et al. Among authors: hickling jk. Lancet. 1996 Jun 1;347(9014):1523-7. doi: 10.1016/s0140-6736(96)90674-1. Lancet. 1996. PMID: 8684105 Clinical Trial.

6

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL. Davidson EJ, et al. Among authors: hickling j. Vaccine. 2004 Jul 29;22(21-22):2722-9. doi: 10.1016/j.vaccine.2004.01.049. Vaccine. 2004. PMID: 15246603 Clinical Trial.

7

Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif.

Tarpey I, Stacey S, Hickling J, Birley HD, Renton A, McIndoe A, Davies DH. Tarpey I, et al. Among authors: hickling j. Immunology. 1994 Feb;81(2):222-7. Immunology. 1994. PMID: 8157270 Free PMC article.

8

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Boursnell ME, et al. Among authors: hickling jk. Vaccine. 1996 Nov;14(16):1485-94. doi: 10.1016/s0264-410x(96)00117-x. Vaccine. 1996. PMID: 9014288 Free PMC article.

9

Herpes virus-specific immune responses in individuals experiencing recurrent genital herpes.

Boswell CM, Duncan IA, Uttridge J, Sonnex C, Hickling JK. Boswell CM, et al. Among authors: hickling jk. Biochem Soc Trans. 1997 May;25(2):278S. doi: 10.1042/bst025278s. Biochem Soc Trans. 1997. PMID: 9191322 No abstract available.

10

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.

de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH, Hickling JK. de Jong A, et al. Among authors: hickling jk. Vaccine. 2002 Oct 4;20(29-30):3456-64. doi: 10.1016/s0264-410x(02)00350-x. Vaccine. 2002. PMID: 12297390 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page